Page values for "Doxepin"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Doxepin (hydrochloride) |
| brand | String | Sinequan (oral antidepressant, US brand discontinued), Silenor (low-dose for insomnia), Prudoxin / Zonalon (topical cream) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Tricyclic antidepressants|Tricyclic antidepressant (TCA)]] • [[:Category:Antidepressants|Antidepressant]] • [[:Category:Sleep aids|Sleep aid (Silenor low-dose)]] • [[:Category:Antihistamines|Antihistamine (potent H1)]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours |
| preparations | String | Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon) |
| fda_max | String | 300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • topical |
| onset | String | Sleep effect from first dose; antidepressant effect over 1-4 weeks |
| duration | String | 24 hours (HS dosing) |
| halflife | String | ~15 hours (parent); nordoxepin active metabolite ~30 hours'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~30% (oral)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | TCA class signal; limited human data specific to doxepin.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' |